Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Randomized, Double Blind Placebo Controlled Trial To Evaluate the Non-interference in the Immune Response of Three Doses of ORV 116E to Antigens Contained in Childhood Vaccines and to Assess the Clinical Lot Consistency of Three Production Lots

Next Previous
X
Search
Trial Profile

A Phase III Randomized, Double Blind Placebo Controlled Trial To Evaluate the Non-interference in the Immune Response of Three Doses of ORV 116E to Antigens Contained in Childhood Vaccines and to Assess the Clinical Lot Consistency of Three Production Lots

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ORV 116E (Primary)
  • Indications Rotavirus infections
  • Focus Therapeutic Use

    • Most Recent Events

    • 23 Sep 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top